Table 3.

Linear regression analysis with log-transformed serum CGRP-LI levels (mol/l) T1

Variable	β (95% CI)1	p	β (95% CI)2	p
Age	0.07 (-0.001–0.13)	0.05	0.044 (-0.03 − 0.12)	0.24
Sex	1.92 (-0.41–4.25)	0.10	2.979 (0.65–5.31)	0.01
Migraine days baseline	0.09 (-0.06–0.24)	0.24	0.10 (-0.06–0.25)	0.22
Serum CGRP-LI	-2.12 (-3.44 - -0.80)	0.002	-2.13 (-3.52 - -0.73)	0.003
N = 89. 1Simple linear regression. 2multiple regression, corrected for all tested variables. CI = confidence interval. T1 = 2–4 weeks after starting treatment with erenumab. The outcome is absolute reduction migraine days during month 3 after starting treatment with erenumab compared to baseline. One month is defined as 28 days.